Description:
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001)
combinations in previously treated unresectable or metastatic melanoma
Title
- Brief Title: Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
- Official Title: A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Clinical Trial IDs
- ORG STUDY ID:
CPDR001J2201
- SECONDARY ID:
2018-000610-38
- NCT ID:
NCT03484923
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Spartalizumab | PDR001 | Arm 1: LAG525 + Spartalizumab in unselected patients |
LAG525 | | Arm 1: LAG525 + Spartalizumab in unselected patients |
Capmatinib | INC280 | Arm 2: Capmatinib+Spartalizumab in unselected patients |
Canakinumab | ACZ885 | Arm 3: Canakinumab+Spartalizumab in unselected patients |
Ribociclib | LEE011 | Arm 4: Ribociclib+Spartalizumab in unselected patients |
Purpose
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001)
combinations in previously treated unresectable or metastatic melanoma
Trial Arms
Name | Type | Description | Interventions |
---|
Arm 1: LAG525 + Spartalizumab in unselected patients | Experimental | Spartalizumab and LAG525 will be administered intravenously | |
Arm 2: Capmatinib+Spartalizumab in unselected patients | Experimental | Spartalizumab will be administered intravenously. Capmatinib will be administered orally. | |
Arm 3: Canakinumab+Spartalizumab in unselected patients | Experimental | Spartalizumab will be administered intravenously. Canakinumab will be administered subcutaneously. | |
Arm 4: Ribociclib+Spartalizumab in unselected patients | Experimental | Spartalizumab will be administered intravenously. Ribociclib will be administered orally. | |
Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients | Experimental | Spartalizumab and LAG525 will be administered intravenously | |
Eligibility Criteria
Key inclusion criteria for Arm 1,2,3,4:
- Histologically confirmed unresectable or metastatic stage IIIB/C/D or IV melanoma
using AJCC edition 8
- Previously treated for unresectable or metastatic melanoma:
- Subjects with V600BRAF wild-type disease must have received prior systemic therapy for
unresectable or metastatic melanoma with anti-PD-1/PD-L1. Additionally, subjects may
have received anti-CTLA-4 as a single agent or in combination with anti-PD-1/PD-L1,
irrespective of the sequence. No additional systemic treatment is allowed for advanced
or metastatic melanoma.
A maximum of two prior lines of systemic therapies for unresectable or metastatic melanoma
are allowed.
The last dose of prior therapy (anti-PD-1, anti-PD-L1 or anti-CTLA-4) must have been
received more than four weeks before randomization.
- Subjects with V600BRAF mutant disease must have received prior systemic therapy for
unresectable or metastatic melanoma with anti-PD-1/PD-L1, and V600BRAF inhibitor.
Additionally, subjects may have received anti-CTLA-4 as a single agent or in
combination with anti-PD-1/PD-L1, or MEK inhibitor (in combination with V600BRAF
inhibitor or as a single agent), irrespective of the sequence. No additional systemic
treatment is allowed for advanced or metastatic melanoma .
A maximum of three prior lines of systemic therapies for unresectable or metastatic
melanoma are allowed.
The last dose of prior therapy must have been received more than 4 weeks (for anti-PD-1,
anti-PD-L1 or anti-CTLA-4) or more than 2 weeks (for V600BRAF or MEK inhibitor) prior to
randomization.
- All subjects (with V600BRAF wild-type disease and with V600BRAF mutant disease) must
have documented disease progression as per RECIST v1.1 while on/after the last therapy
received prior to study entry and while on/after treatment with anti-PD1/PD-L1. The
last progression must have occured within 12 weeks prior to randomization in the
study.
- ECOG performance status 0-2
- At least one measurable lesion per RECIST v1.1
- At least one lesion, suitable for sequential mandatory tumor biopsies (screening and
on-treatment) in accordance with the biopsy guidelines specified in protocol. The same
lesion must be biopsied sequentially.
- Screening tumor biopsy must fulfill the tissue quality criteria outlined in the
protocol, as assessed by a local pathologist
Key inclusion criteria for Arm 1A:
- Histologically confirmed unresectable or metastatic stage IIIB/C/D or IV melanoma
according to AJCC Edition 8
- Previously treated for unresectable or metastatic melanoma:
- All subjects must have received anti-PD-1 checkpoint inhibitor therapy (ie.
pembrolizumab or nivolumab) either as monotherapy or in combination with
ipilimumab as the last systemic therapy prior to enrollment and must have
confirmed disease progression as per RECIST v1.1 (confirmed on a subsequent scan,
which can be the scan performed during screening) while on or after this therapy
prior to enrollment.
- Subjects with V600BRAF wild-type disease must have received no more than 2 prior
systemic therapies including prior anti-PD-1/PD-L1 (as monotherapy or in
combination with ipilimumab)
- Subjects with V600BRAF mutant disease must have received no more than 3 prior
systemic therapies including anti-PD-1/PD-L1 (as monotherapy or in combination
with ipilimumab), and V600BRAF inhibitor (as monotherapy or in combination with a
MEK inhibitor)
- The last dose of anti-PD-1 based therapy must have been received more than four
weeks prior to first dose of study treatment.
- The last documented disease progression must have occurred within 12 weeks prior
to first dose of study treatment
- No additional systemic treatment is allowed for advanced or metastatic melanoma
(this includes for example tumor infiltrating lymphocyte therapy)
- ECOG performance status 0-1
- At least one measurable lesion per RECIST v1.1
- Subjects must have baseline tumor sample that is positive for LAG-3 per central
assessment
Key exclusion criteria common to all combination arms:
- Subjects with uveal or mucosal melanoma
- Presence of clinically active or unstable brain metastasis at time of screening.
- Use of any live vaccines against infectious diseases within 3 months before
randomization/enrolment.
- Active infection requiring systemic antibiotic therapy at time of
randomization/enrolment.
- Subjects with a condition requiring systemic treatment with either corticosteroids
(>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
days of randomization/enrollment. Inhaled or topical steroids, and adrenal replacement
steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of
active autoimmune disease.
- Active, known or suspected autoimmune disease or a documented history of autoimmune
disease.
- Prior allogenic bone marrow or solid organ transplant
- History of known hypersensitivity to any of the investigational drugs used in this
study
- Prior systemic therapy for unresectable or metastatic melanoma with any
investigational agent, or with any other agent except anti-PD-1/PD-L1 and anti-CTLA-4
(and V600BRAF and MEK inhibitors if subject has V600BRAF mutant disease). Prior
neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months before
the start of the study treatment
- Medical history or current diagnosis of myocarditis
- Cardiac Troponin T (or Troponin I) level > 2 x ULN at screening
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Overall Response Rate (ORR) |
Time Frame: | 38 months |
Safety Issue: | |
Description: | ORR defined as the proportion of patients with a best overall response of either confirmed complete response or confirmed partial response (as per local review and according to RECIST v1.1) |
Secondary Outcome Measures
Measure: | Duration of Response |
Time Frame: | Up to disease progression or death due to any cause, whichever occurs first (3 years) |
Safety Issue: | |
Description: | DOR defined as the time from date of first documented complete response or partial response to date of first documented disease progression or death due to any cause (as per local review and according to RECIST v1.1) |
Measure: | Overall Survival (OS) |
Time Frame: | Up to death due to any cause (3 years) |
Safety Issue: | |
Description: | OS defined as time from date of randomization (or date of first dose of study treatment in arm 1A) to date of death due to any cause |
Measure: | Progression Free Survival (PFS) |
Time Frame: | Up to disease progression or death due to any cause, whichever occurs first (3 years) |
Safety Issue: | |
Description: | PFS defined as the interval of time between the date of randomization (or date of first dose of study treatment in arm 1A) to the date of event defined as the first documented disease progression or death due to any cause (as per local review and according to RECIST v1.1) |
Measure: | Disease Control Rate (DCR) |
Time Frame: | Up to disease progression or death due to any cause, whichever occurs first (3 years) |
Safety Issue: | |
Description: | DCR defined as the proportion of patients with best overall response of complete response, partial response, or stable disease (as per local review and according to RECIST v1.1) |
Measure: | Prevalence of anti-drug antibodies (ADA) prevalence at baseline |
Time Frame: | At Baseline |
Safety Issue: | |
Description: | Number of patients with presence of anti-drug antibodies (ADA) |
Measure: | Incidence of anti-drug antibodies (ADA) |
Time Frame: | Throughout study until 150 day after last drug administration |
Safety Issue: | |
Description: | Number of patients developing new anti-drug antibodies (ADA) |
Measure: | Percentage of subjects with a favorable biomarker profile (pFBP) |
Time Frame: | Baseline and after 3-4 weeks on treatment |
Safety Issue: | |
Description: | pFBP defined by changes in number of cells expressing the CD8+ T cell marker and/or T cell activation marker(s), T cell clonality and/or gene expression tumor biosy samples. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Novartis Pharmaceuticals |
Trial Keywords
- Unresectable
- melanoma
- metastatic melanoma
- advanced melanoma
- spartalizumab
- PDR001
- LAG525
- capmatinib
- INC280
- canakinumab
- ACZ885
- ribociclib
- LEE011
- immunotherapy
- platform study
- LAG-3
Last Updated
February 26, 2021